Genocea: Rises as FDA gives nod for start of cancer therapy study

Genocea Biosciences

22/09/2020 13:02

** Drug developer's shares  GNCA.O  rise 5.6% to $2.45
premarket
    ** Co says U.S.FDA accepts its Investigational New Drug
(IND) application for GEN-011, allowing co to begin early stage
studies 
    ** Co plans to enroll up to 24 patients with several tumor
types in its early studies
    ** GEN-011 is an adoptive T cell therapy targeting
neoantigens, or newly formed antigens that have not been
previously recognized by the immune system 
    ** T cells are part of the immune system and help protect
the body from infection
    ** Co says GEN-011 is designed to improve upon limitations
of existing cell therapies
    ** Up to last close, GNCA stock up ~12% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))